Latest Research And Development News

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Assetora Limited disclosed a $341,000 net operating cash outflow for the September 2025 quarter, supported by $1.6 million in total available funding including cash reserves and financing facilities.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

Global Health Limited has accelerated its MasterCare+ SaaS platform rollout, integrating AI to streamline operations and reduce staff by 10%, while reporting a 25% EBIT improvement despite a delayed R&D refund impacting cash flow.

NOVONIX has reached mutual agreement to draw down an additional US$40 million tranche of convertible debentures from Yorkville Advisors, advancing its funding strategy to support growth in battery technology.

Ardea Resources reports strong progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, including high-grade drilling results, a heritage agreement, and consortium funding support. Completion of the DFS is now targeted for mid-2026 amid ongoing ESG and stakeholder engagement.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

AML3D Limited reported steady quarterly receipts alongside a landmark US Navy Letter of Intent and significant orders, underpinning a major growth phase in the US and Europe.

Phoslock Environmental Technologies reported a $952,000 operating cashflow deficit in Q3 2025 amid rising legal and logistics expenses, while sales volumes improved and production is set to resume in early 2026.

International Graphite Limited has taken significant steps toward establishing Australia’s first commercial graphite micronising plant with land acquisition and key development approvals in Collie, WA.